Published in Cardiovasc Diabetol on March 23, 2010
Chronic inflammation in obesity and the metabolic syndrome. Mediators Inflamm (2010) 2.18
Interleukin-18 and IL-18 binding protein. Front Immunol (2013) 1.93
The effects of the mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. PLoS One (2014) 1.33
Prevalence of metabolic syndrome in South Indian patients with psoriasis vulgaris and the relation between disease severity and metabolic syndrome: a hospital-based case-control study. Indian J Dermatol (2012) 1.28
The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol (2010) 1.16
"The metabolic syndrome... is dead": these reports are an exaggeration. Cardiovasc Diabetol (2011) 1.08
Inflammasomes and metabolic disorders: old genes in modern diseases. Mol Cell (2014) 1.06
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol (2011) 0.88
The immune protective effect of the Mediterranean diet against chronic low-grade inflammatory diseases. Endocr Metab Immune Disord Drug Targets (2014) 0.86
Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J Neuroinflammation (2014) 0.85
Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy. Physiol Genomics (2011) 0.84
Adipose tissue expression of interleukin-18 mRNA is elevated in subjects with metabolic syndrome and independently associated with fasting glucose. Wien Klin Wochenschr (2011) 0.83
Differences in plasma cytokine levels between elite kayakers and nonathletes. Biomed Res Int (2013) 0.81
Effects of human immunodeficiency virus and metabolic complications on myocardial nutrient metabolism, blood flow, and oxygen consumption: a cross-sectional analysis. Cardiovasc Diabetol (2011) 0.81
Neuroendocrine and cardiac metabolic dysfunction and NLRP3 inflammasome activation in adipose tissue and pancreas following chronic spinal cord injury in the mouse. ASN Neuro (2013) 0.81
Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome. Nutr Metab (Lond) (2011) 0.80
A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus. PLoS One (2016) 0.79
Association of insulin resistance with adipocytokine levels in patients with metabolic syndrome. Indian J Clin Biochem (2014) 0.78
A novel inflammatory biomarker, GlycA, associates with disease activity in rheumatoid arthritis and cardio-metabolic risk in BMI-matched controls. Arthritis Res Ther (2016) 0.78
Metabolic syndrome and inflammation: a critical review of in vitro and clinical approaches for benefit assessment of plant food supplements. Evid Based Complement Alternat Med (2013) 0.77
Increased expression of IL-18 in the serum and islets of type 1 diabetics. Mol Immunol (2015) 0.77
Obesity development in caspase-1-deficient mice. Int J Obes (Lond) (2013) 0.77
Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18. PLoS One (2013) 0.77
Offspring subcutaneous adipose markers are sensitive to the timing of maternal gestational weight gain. Reprod Biol Endocrinol (2015) 0.75
Joint Profiling of miRNAs and mRNAs Reveals miRNA Mediated Gene Regulation in the Göttingen Minipig Obesity Model. PLoS One (2016) 0.75
Particulate Air pollution mediated effects on insulin resistance in mice are independent of CCR2. Part Fibre Toxicol (2017) 0.75
Gut Balance, a synbiotic supplement, increases fecal Lactobacillus paracasei but has little effect on immunity in healthy physically active individuals. Gut Microbes (2012) 0.75
Evaluation of Biomarkers in Egyptian Patients with Different Grades of Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol (2017) 0.75
Per os colchicine administration in cholesterol fed rabbits: Triglycerides lowering effects without affecting atherosclerosis progress. Lipids Health Dis (2017) 0.75
Increased adipose tissue expression of IL-18R and its ligand IL-18 associates with inflammation and insulin resistance in obesity. Immun Inflamm Dis (2017) 0.75
The association between cigarette smoking and inflammation: The Genetic Epidemiology Network of Arteriopathy (GENOA) study. PLoS One (2017) 0.75
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation (2005) 43.74
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest (2003) 41.22
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest (2003) 32.01
Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 25.68
The metabolic syndrome--a new worldwide definition. Lancet (2005) 23.51
The metabolic syndrome. Lancet (2005) 19.47
Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 10.89
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol (2007) 7.79
Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care (2004) 6.68
Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA (2004) 6.38
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation (2002) 6.26
Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol (2008) 5.56
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 5.44
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol (2008) 5.19
Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 4.76
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 3.56
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Impaired leucocyte functions in diabetic patients. Diabet Med (1997) 3.33
Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol (2005) 3.15
The IL-1 family and inflammatory diseases. Clin Exp Rheumatol (2004) 3.10
Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation (2005) 3.02
The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol (2005) 2.92
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation (2004) 2.90
Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nat Med (2006) 2.86
Interleukin-18. J Leukoc Biol (2003) 2.75
Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring) (2007) 2.68
Purification and characterization of the human interleukin-18 receptor. J Biol Chem (1997) 2.58
Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev (2001) 2.52
NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr Opin Immunol (2008) 2.45
Interleukin-18 and the pathogenesis of inflammatory diseases. Semin Nephrol (2007) 2.35
Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation (2003) 2.26
Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr (2006) 2.22
Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 2.18
Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol (2005) 2.17
Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation (2001) 2.13
T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol (2006) 2.12
Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes (2005) 1.98
Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med (2002) 1.91
Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial factors in older adults. Brain Behav Immun (2006) 1.86
Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes Care (2003) 1.81
The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil (2007) 1.61
Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring) (2006) 1.59
Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) (2008) 1.59
A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. J Immunol (1997) 1.58
Obesity, metabolic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev (2007) 1.50
Elevated glucose and diabetes promote interleukin-12 cytokine gene expression in mouse macrophages. Endocrinology (2006) 1.47
Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol (2006) 1.46
Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J (2002) 1.45
The structure and binding mode of interleukin-18. Nat Struct Biol (2003) 1.42
A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine (2001) 1.41
Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab (2002) 1.40
Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol (2007) 1.22
Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab (2006) 1.22
Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol (2007) 1.20
Combined diet and exercise intervention reverses the metabolic syndrome in middle-aged males: results from the Oslo Diet and Exercise Study. Scand J Med Sci Sports (2007) 1.19
Neutrophil bactericidal function in diabetes mellitus: evidence for association with blood glucose control. Diabet Med (1995) 1.18
Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol (2005) 1.13
Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res (2005) 1.12
Nod-like receptors: cytosolic watchdogs for immunity against pathogens. PLoS Pathog (2007) 1.12
The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol (2005) 1.11
Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels. Arterioscler Thromb Vasc Biol (2010) 1.10
Gamma interferon: a central mediator in atherosclerosis. Inflamm Res (2005) 1.09
Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol (2004) 1.07
The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. J Clin Endocrinol Metab (2008) 1.07
IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine (2008) 1.06
The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFalpha in human adipocytes. Biochem Biophys Res Commun (2005) 1.06
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol (2006) 1.06
Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol (2001) 1.04
Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia (2009) 1.04
Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol (2005) 1.02
Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care (2005) 1.02
Fiber type specific expression of TNF-alpha, IL-6 and IL-18 in human skeletal muscles. Exerc Immunol Rev (2005) 1.00
Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care (2003) 1.00
Increased serum interleukin-18 concentration is associated with hypoadiponectinemia in obesity, independently of insulin resistance. Int J Obes (Lond) (2006) 0.99
Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome. Metabolism (2008) 0.99
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol (2008) 0.98
The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease. Nat Clin Pract Cardiovasc Med (2009) 0.97
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail (2007) 0.96
Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond) (2008) 0.96
Increased cardiac IL-18 mRNA, pro-IL-18 and plasma IL-18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction. Cardiovasc Res (2003) 0.94
Adipose tissue interleukin-18 mRNA and plasma interleukin-18: effect of obesity and exercise. Obesity (Silver Spring) (2007) 0.92
Interleukin 18 in the heart. Shock (2008) 0.91
Circulating IL-18 concentration is associated with insulin sensitivity and glucose tolerance through increased fat-free mass. Diabetologia (2005) 0.90
Intermittent high glucose stimulate MCP-l, IL-18, and PAI-1, but inhibit adiponectin expression and secretion in adipocytes dependent of ROS. Cell Biochem Biophys (2009) 0.90
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis (2000) 0.89
Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil (2008) 0.88
Interleukin-18 contributes more closely to the progression of diabetic nephropathy than other diabetic complications. Acta Diabetol (2010) 0.87
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord (2009) 0.87
IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis (2009) 0.87
IL-18 overexpression promotes vascular inflammation and remodeling in a rat model of metabolic syndrome. Atherosclerosis (2009) 0.87
Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis (2008) 0.87
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism (2009) 0.85
Lack of association between polymorphisms of the IL18R1 and IL18RAP genes and cardiovascular risk: the MORGAM Project. BMC Med Genet (2009) 0.84
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med (2006) 7.28
Warfarin, aspirin, or both after myocardial infarction. N Engl J Med (2002) 6.85
The anesthesia in abdominal aortic surgery (ABSENT) study: a prospective, randomized, controlled trial comparing troponin T release with fentanyl-sevoflurane and propofol-remifentanil anesthesia in major vascular surgery. Anesthesiology (2013) 3.38
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Low heart rates predict incident atrial fibrillation in healthy middle-aged men. Circ Arrhythm Electrophysiol (2013) 2.12
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res (2005) 1.62
Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol (2012) 1.60
Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol (2012) 1.58
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension (2012) 1.57
Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol (2007) 1.48
The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. Scand J Clin Lab Invest (2010) 1.45
Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol (2006) 1.45
Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J (2013) 1.44
Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism (2007) 1.42
Less benefit from warfarin in diabetics after myocardial infarction? Cardiology (2008) 1.40
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
Frequency of left ventricular thrombus in patients with anterior wall acute myocardial infarction treated with percutaneous coronary intervention and dual antiplatelet therapy. Am J Cardiol (2010) 1.30
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost (2009) 1.21
Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J (2005) 1.21
Patients' experiences with symptoms and needs in the early rehabilitation phase after coronary artery bypass grafting. Eur J Cardiovasc Nurs (2012) 1.17
High prevalence of atrial fibrillation in long-term endurance cross-country skiers: echocardiographic findings and possible predictors--a 28-30 years follow-up study. Eur J Cardiovasc Prev Rehabil (2010) 1.15
Abnormal glucose regulation in patients with acute ST- elevation myocardial infarction-a cohort study on 224 patients. Cardiovasc Diabetol (2009) 1.15
Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes (2002) 1.14
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism (2004) 1.10
Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res (2002) 1.06
Dairy products and metabolic effects in overweight men and women: results from a 6-mo intervention study. Am J Clin Nutr (2009) 1.02
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia. Am J Clin Nutr (2005) 1.00
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care (2008) 0.98
Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol (2008) 0.98
Age and stress related phenotypical changes in bone marrow CD34+ cells. Scand J Clin Lab Invest (2009) 0.95
The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care (2012) 0.95
Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis (2003) 0.94
Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart (2011) 0.94
Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur J Cardiovasc Prev Rehabil (2006) 0.94
No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J (2002) 0.93
Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes. Scand J Clin Lab Invest (2009) 0.93
Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J (2004) 0.92
Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta (2011) 0.92
Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers. BMC Med (2010) 0.91
Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest (2008) 0.90
Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism (2013) 0.90
Importance of physical fitness on predictive effect of body mass index and weight gain on incident atrial fibrillation in healthy middle-age men. Am J Cardiol (2012) 0.90
Regional myocardial function after intracoronary bone marrow cell injection in reperfused anterior wall infarction - a cardiovascular magnetic resonance tagging study. J Cardiovasc Magn Reson (2011) 0.89
Frailty measures, inflammatory biomarkers and post-operative complications in older surgical patients. Age Ageing (2010) 0.89
High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc (2012) 0.89
Circulating levels of IL-18 are significantly influenced by the IL-18 +183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol (2011) 0.88
Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin Sci (Lond) (2003) 0.88
Effect of lifestyle changes on atherogenic lipids and endothelial cell adhesion molecules in young adults with familial premature coronary heart disease. Am J Cardiol (2005) 0.88
A comparison of the effects of cheese and butter on serum lipids, haemostatic variables and homocysteine. Br J Nutr (2004) 0.88
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome. Metab Syndr Relat Disord (2009) 0.87
Activin A levels are associated with abnormal glucose regulation in patients with myocardial infarction: potential counteracting effects of activin A on inflammation. Diabetes (2011) 0.86
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. J Biomed Biotechnol (2010) 0.86
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis (2002) 0.86
Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail (2013) 0.86
Influence of aspirin on inflammatory markers in patients after acute myocardial infarction. Am J Cardiol (2003) 0.86
Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study. Cardiovasc Diabetol (2010) 0.85
Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism (2009) 0.85
Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J (2010) 0.85
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res (2002) 0.84
Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J (2008) 0.84
The profile of circulating metalloproteinases after PCI in patients with acute myocardial infarction or stable angina. Thromb Res (2009) 0.84
Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study. Nutr Metab Cardiovasc Dis (2008) 0.84
Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial. J Psychosom Res (2007) 0.84
A long-term follow-up study of chest pain patients: effect of panic disorder on mortality, morbidity, and quality of life. Cardiology (2007) 0.84